30-day average of 14 articles Β· scale β100 to +100
Across 14 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Boston Scientific news is Neutral (+1)
on a scale from β100 to +100.
That is up 9 points from the previous 30 days (-8).
π WATCHMAN FLX Pro trials show noninferiority with reduced bleeding risks.
π Global recalls for Neuromodulation discs and microcatheters create operational risks.
Slightly Bullish +15
Boston Scientific stock faces recall scrutiny across device lines
AI-generated analysis
Key insights
π Boston Scientific faces operational risks from multiple Class II recalls involving Neuromodulation therapy discs and Direxion Torqueable Microcatheters distributed globally.
β οΈ Quality control issues could lead to rework costs, regulatory scrutiny, and disruption in interventional and neuromodulation product lines.
π Recalls add pressure to the WATCHMAN and electrophysiology franchises which are already facing volume trends challenges.
π Recent trial results for the WATCHMAN FLX Pro device demonstrated noninferiority with reduced bleeding risks compared to dual antiplatelet therapy.
π Analysts project US$23.0 billion revenue and US$4.0 billion earnings by 2029 based on a 2.9% annual growth rate.
π Optimistic estimates suggest potential for US$24.4 billion revenue and US$4.4 billion earnings by 2029 if execution targets are met.
π€ The company's future performance depends on offsetting weaker franchises with its cardiovascular and MedSurg portfolios.
π° Strategic growth relies on successful restructuring savings and the integration of the planned Penumbra acquisition.
π Bullish signals
πRecent clinical trial results for the WATCHMAN FLX Pro device showed noninferiority for aspirin alone or reduced-dose NOAC regimens versus dual antiplatelet therapy at six months.
πThe findings from the WATCHMAN FLX Pro trials indicate similar ischemic stroke rates and less bleeding, which could support the franchise if left atrial appendage closure volumes stabilize.
π Risk factors
πMultiple Class II recalls reported in 2026 involving firmware problems in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters raise potential remediation costs.
πQuality control issues associated with recent recalls add operational risk to a portfolio already facing pressure in electrophysiology and WATCHMAN product lines.
Article
Boston Scientific faces renewed investor scrutiny following multiple voluntary Class II device recalls reported in 2026, specifically involving firmware issues in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters. These quality control incidents introduce operational risks regarding potential remediation costs, tighter regulatory oversight, and possible disruption to the company's interventional and neuromodulation product lines.
The analysis highlights that these recall risks compound existing pressures within the WATCHMAN and electrophysiology franchises. While Simply Wall St notes that recent trial results for the WATCHMAN FLX Pro device show promising noninferiority outcomes, the broader investment case remains contingent on the company's cardiovascular and MedSurg portfolios offsetting weaker performance in specific areas.
Analysts project Boston Scientific to generate US$23.0 billion in revenue and US$4.0 billion in earnings by 2029, with more optimistic estimates reaching US$24.4 billion in revenue and US$4.4 billion in earnings. These long-term forecasts depend heavily on successful product quality maintenance, supply reliability, and the integration of the planned Penumbra acquisition to sustain growth.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Boston Scientific faces renewed investor scrutiny following multiple voluntary Class II device recalls reported in 2026, specifically involving firmware issues in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters. These quality control incidents introduce operational risks regarding potential remediation costs, tighter regulatory oversight, and possible disruption to the company's interventional and neuromodulation product lines.
The analysis highlights that these recall risks compound existing pressures within the WATCHMAN and electrophysiology franchises. While Simply Wall St notes that recent trial results for the WATCHMAN FLX Pro device show promising noninferiority outcomes, the broader investment case remains contingent on the company's cardiovascular and MedSurg portfolios offsetting weaker performance in specific areas.
Analysts project Boston Scientific to generate US$23.0 billion in revenue and US$4.0 billion in earnings by 2029, with more optimistic estimates reaching US$24.4 billion in revenue and US$4.4 billion in earnings. These long-term forecasts depend heavily on successful product quality maintenance, supply reliability, and the integration of the planned Penumbra acquisition to sustain growth.
π Global recalls for Neuromodulation discs and microcatheters create operational risks.
β οΈ Quality issues threaten interventional lines with rework costs and regulatory scrutiny.
π WATCHMAN FLX Pro trials show noninferiority with reduced bleeding risks.
π Analysts project US$23B revenue and US$4B earnings by 2029.
π Boston Scientific faces operational risks from multiple Class II recalls involving Neuromodulation therapy discs and Direxion Torqueable Microcatheters distributed globally.
β οΈ Quality control issues could lead to rework costs, regulatory scrutiny, and disruption in interventional and neuromodulation product lines.
π Recalls add pressure to the WATCHMAN and electrophysiology franchises which are already facing volume trends challenges.
π Recent trial results for the WATCHMAN FLX Pro device demonstrated noninferiority with reduced bleeding risks compared to dual antiplatelet therapy.
π Analysts project US$23.0 billion revenue and US$4.0 billion earnings by 2029 based on a 2.9% annual growth rate.
π Optimistic estimates suggest potential for US$24.4 billion revenue and US$4.4 billion earnings by 2029 if execution targets are met.
π€ The company's future performance depends on offsetting weaker franchises with its cardiovascular and MedSurg portfolios.
π° Strategic growth relies on successful restructuring savings and the integration of the planned Penumbra acquisition.
Bullish Signals
WATCHMAN FLX Pro showed noninferiority vs dual antiplatelet therapy at six months.
Trials indicate lower bleeding risks for the LAA closure franchise.
Risk Factors
Class II recalls raise 2026 remediation costs for firmware defects.
Quality control issues add operational risk to EP/WATCHMAN lines.
Bullish Signals
Recent clinical trial results for the WATCHMAN FLX Pro device showed noninferiority for aspirin alone or reduced-dose NOAC regimens versus dual antiplatelet therapy at six months.
The findings from the WATCHMAN FLX Pro trials indicate similar ischemic stroke rates and less bleeding, which could support the franchise if left atrial appendage closure volumes stabilize.
Risk Factors
Multiple Class II recalls reported in 2026 involving firmware problems in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters raise potential remediation costs.
Quality control issues associated with recent recalls add operational risk to a portfolio already facing pressure in electrophysiology and WATCHMAN product lines.
S&P Global Ratings has revised Boston Scientific's credit outlook to negative while affirming its A- issuer and senior unsecured debt ratings. This downgrade reflects increased pressure on key business segments, specifically the WATCHMAN left atrial appendage closure franchise and the electrophysiology division, which together account for a significant portion of the company's revenue.
The agency cites weaker-than-expected third-quarter results and a subsequent reduction in 2026 guidance as primary drivers for this assessment. S&P forecasts revenue growth of 4.4% for 2026 and 9% for 2027, marking a notable slowdown from the mid-to-high-teens growth rates achieved in 2024 and 2025. The outlook highlights specific headwinds including clinical trial data uncertainty affecting physician confidence in WATCHMAN procedures and intensifying competition in the electrophysiology market.
Furthermore, Boston Scientific's planned acquisition of Penumbra for $14.5 billion is expected to significantly increase leverage, pushing adjusted leverage ratios above 3.6 times at closing. This transaction adds substantial debt load that will remain elevated through 2028 as the company integrates the neurovascular and cardiovascular therapies portfolio. To restore a stable outlook, management must successfully execute cost-saving initiatives targeting $500 million in savings by 2029 while stabilizing market share in pressured franchises.
Currently trading at 39.40 euros, Boston Scientific faces a critical path to lower leverage that depends on disciplined capital allocation and renewed operating growth. The company has announced plans to limit additional acquisitions and share repurchases during the integration period. A return to a stable credit rating will require mid-single-digit growth in other core franchises alongside improved performance from WATCHMAN and electrophysiology to offset the debt burden from the Penumbra deal.
π S&P downgrades outlook to negative due to WATCHMAN and EP franchise pressure.
π Revenue growth forecast slows to 4.4% in 2026 and 9% in 2027.
β οΈ WATCHMAN faces headwinds from clinical uncertainty and intensifying competition.
π° $14.5B Penumbra acquisition expected to close early 2027, raising leverage above 3.6x.
π Restructuring targets $500M savings by 2029 to restore growth and lower debt.
π S&P Global Ratings revised Boston Scientific's credit outlook to negative, citing continued pressure on its WATCHMAN and electrophysiology franchises.
π Revenue growth is forecast at 4.4% for 2026 and 9% for 2027, a significant deceleration from the mid-to-high-teens rates seen in 2024 and 2025.
β οΈ The WATCHMAN franchise accounts for 10% of revenue and faces headwinds from clinical trial data uncertainty and intensifying competition.
π₯ The electrophysiology division, contributing 16% of sales, is weighed down by competition from Johnson & Johnson, Medtronic, and Abbott.
π° The planned $14.5 billion acquisition of Penumbra is expected to close in early 2027, driving adjusted leverage above 3.6 times.
π S&P expects management to limit additional acquisitions and share repurchases while integrating the Penumbra transaction and reducing debt.
πΈ Boston Scientific has launched a restructuring program targeting $500 million in cost savings through 2029 to restore growth and lower leverage.
π A return to a stable credit outlook requires mid-single-digit growth in core franchises and leverage reduction below the 2.5-times downside trigger.
πΆ Boston Scientific stock traded at 39.40 euros on November 10, 2026, reflecting concerns over execution risk and financing costs.
Bullish Signals
Penumbra acquisition adds $1.4B 2025 revenue.
Diversified portfolio offsets franchise weakness.
Risk Factors
S&P downgraded outlook due to weak Q3 results and lower 2026 guidance.
Bullish Signals
The acquisition of Penumbra offers a growth opportunity with roughly $1.4 billion in 2025 revenue, operating in complementary neurovascular and cardiovascular therapies.
Boston Scientific's diversified cardiovascular and MedSurg portfolio remains a counterweight to the weakness observed in its two pressured franchises.
Risk Factors
S&P Global Ratings revised the credit outlook to negative due to weaker-than-expected third-quarter results and a reduction in 2026 guidance.
Revenue growth is projected to slow to 4.4% in 2026 and 9% in 2027, well below the mid-to-high-teens rates achieved in 2024 and 2025.
The WATCHMAN franchise faces headwinds from clinical trial data uncertainty that increased physician hesitation and intensifying market competition.
The electrophysiology franchise is under pressure from strong competitors including Johnson & Johnson, Medtronic, and Abbott, weighing on market share recovery.
The $14.5 billion Penumbra acquisition will push adjusted leverage above 3.6 times at closing, significantly increasing financial risk compared to the 2.5-times downside trigger.
Elevated leverage is expected to remain high for two years following the deal as Boston Scientific integrates the acquired business and manages debt obligations.
S&P Global Ratings has revised Boston Scientific's credit outlook to negative from stable, citing weakening growth in its WATCHMAN and electrophysiology franchises. The agency affirmed the company's A- issuer rating but highlighted concerns over pressure on these two key business segments which have historically driven significant expansion.
The medical device maker faces a planned acquisition of Penumbra for 14.5 billion US dollars, expected to close in early 2027. S&P projects that this deal will push the company's adjusted leverage above 3.6 times after closing, significantly exceeding its 2.5-times downside trigger and keeping debt levels elevated for an extended period.
Revenue growth forecasts have been lowered to 4.4 percent for 2026 and 9 percent in 2027, marking a decline from the mid- to high-teens growth rates achieved in 2024 and 2025. Management plans to pursue approximately 500 million US dollars in restructuring savings through 2029 to manage costs while integrating Penumbra and stabilizing core franchises.
The central challenge for investors is whether Boston Scientific's broader portfolio can offset the specific pressures in its WATCHMAN and electrophysiology units. The negative outlook depends on successful integration of Penumbra, restoration of growth in key areas, and a return to leverage targets by the end of 2028.
π S&P downgrades outlook to negative due to WATCHMAN and electrophysiology pressure.
π° $14.5B Penumbra deal expected to close early 2027, raising leverage risk.
π Revenue growth forecasts lowered to 4.4% for 2026 and 9% for 2027.
πΈ Plans $500M restructuring savings through 2029 to manage integration costs.
π S&P Global Ratings revised Boston Scientific's credit outlook to negative from stable due to pressure on WATCHMAN and electrophysiology franchises.
π° The planned 14.5 billion US dollar acquisition of Penumbra is expected to close in early 2027, adding significant leverage risk.
π Revenue growth forecasts were lowered to 4.4 percent for 2026 and 9 percent for 2027, below the mid- to high-teens rates seen previously.
βοΈ Adjusted leverage is projected to rise above 3.6 times after the Penumbra deal closes, well above the 2.5-times downside trigger.
πΈ The company plans to pursue 500 million US dollars in restructuring savings through 2029 to manage financial policy and integration costs.
π― Management aims to work back toward a leverage ratio of 2.5 times by the end of 2028, contingent on successful execution.
π₯ Investors are focused on whether the broader portfolio can offset weakness in two important growth franchises while integrating Penumbra.
Risk Factors
S&P downgraded credit outlook to negative due to franchise pressure.
Risk Factors
S&P Global Ratings revised Boston Scientific's credit outlook to negative from stable, citing pressure on WATCHMAN and electrophysiology franchises.
The planned 14.5 billion US dollar acquisition of Penumbra is expected to push adjusted leverage above 3.6 times after closing, exceeding the 2.5-times downside trigger.
Revenue growth forecasts were lowered to 4.4 percent for 2026 and 9 percent for 2027, representing a significant deceleration from mid- to high-teens growth rates achieved in 2024 and 2025.
The negative outlook depends on the company's ability to stabilize WATCHMAN, restore electrophysiology growth, and successfully integrate Penumbra while maintaining conservative financial policy.
Boston Scientific reported its third-quarter 2026 results on October 28, providing an operational update for investors ahead of the new month. The company maintained focus on execution across its medical-device portfolio while releasing key financial and strategic developments.
On November 2, the company announced that the SIMPLAAFY study for its WATCHMAN FLX Pro device successfully met its primary endpoints. This clinical update regarding post-implant treatment options aims to broaden the evidence base for the WATCHMAN platform, potentially influencing adoption discussions.
Looking ahead, Boston Scientific is scheduled to participate in Stifel's 2026 Healthcare Conference on November 11. The stock was trading at 38.39 euros as of Saturday, November 7, 2026, reflecting market attention on these quarterly and clinical milestones.
π BSX released Q3 2026 results on October 28.
β WATCHMAN FLX Pro study met primary endpoints Nov 2.
π¬ Clinical update expands evidence for WATCHMAN platform.
ποΈ BSX presents at Stifel Healthcare Conference Nov 11.
π° Stock traded at 38.39 euros on Nov 7, 2026.
π Boston Scientific released its third-quarter 2026 results on October 28, offering the latest operating update before the new month.
β The SIMPLAAFY study for the WATCHMAN FLX Pro device met its primary endpoints on November 2, advancing clinical evidence.
π¬ The clinical update supports efforts to broaden the evidence base around the WATCHMAN platform and post-implant treatment options.
ποΈ The company is scheduled to present at Stifel's 2026 Healthcare Conference on November 11.
π° Boston Scientific stock traded at 38.39 euros on Lang & Schwarz as of Saturday, November 7, 2026.
Bullish Signals
Boston Scientific met primary endpoints for SIMPLAAFY study on Nov 2.
Boston Scientific successfully met primary endpoints for the SIMPLAAFY study of its WATCHMAN FLX Pro device on November 2.
The positive clinical update regarding post-implant treatment options strengthens the company's effort to broaden evidence around the WATCHMAN platform.
Blackstone Life Sciences (BXLS) has announced a $455 million strategic collaboration with Boston Scientific Corp. to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System program. This partnership marks the first instance where Blackstone Life Sciences and Boston Scientific will jointly fund the development of a product within Boston Scientific's portfolio.
The VITALYST system is designed as a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It specifically targets acute myocardial infarction cardiogenic shock (AMI-CS), a life-threatening medical emergency where the heart fails to pump sufficient oxygenated blood to critical organs.
The collaboration aims to address significant unmet needs for critically ill patients suffering from cardiogenic shock, which is associated with high mortality rates despite existing treatment advances. The VITALYST system focuses on improving efficacy, safety, and ease of use for physicians treating these complex cases, leveraging Boston Scientific's established expertise in cardiovascular technologies.
π€ Blackstone Life Sciences partners with Boston Scientific on $455M VITALYST pump deal.
βοΈ System engineered to improve efficacy, safety, and ease of use for physicians.
π€ Blackstone Life Sciences and Boston Scientific Corp. have entered a $455 million collaboration to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System.
π This partnership represents the first time Blackstone Life Sciences and Boston Scientific will co-fund the development of a Boston Scientific product, highlighting a new strategic approach.
π― The initiative targets acute myocardial infarction cardiogenic shock (AMI-CS), addressing core unmet needs for critically ill patients with high mortality rates.
βοΈ The VITALYST system is engineered to improve efficacy, safety, and ease of use for physicians treating complex cardiovascular emergencies.
Bullish Signals
Secured $455M collaboration for VITALYST system development.
First joint funding signals strong confidence in technology.
Addresses unmet needs in acute myocardial infarction shock.
Bullish Signals
Blackstone Life Sciences has secured a $455 million collaboration with Boston Scientific Corp. to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System.
The partnership marks the first time Blackstone Life Sciences and Boston Scientific will jointly fund the development of a product, signaling strong confidence in the technology's potential.
The VITALYST system is designed to address significant unmet needs in treating acute myocardial infarction cardiogenic shock, a life-threatening condition with high mortality rates.
Boston Scientific Corporation (BSX) has recently been a trending stock, with shares gaining +10.2% over the past month compared to the S&P 500's decline. The company operates within the Zacks Medical Products industry, which has seen significant gains during this period. However, fundamental analysis suggests caution due to recent downward revisions in earnings projections.
Analysts have lowered their consensus earnings estimates for the current quarter by -2.5% and for the fiscal year by -2.6%. Consequently, Boston Scientific has received a Zacks Rank #5 (Strong Sell), indicating a high probability of near-term underperformance relative to the broader market. This rating is driven primarily by negative trends in earnings estimate revisions over the last 30 days.
Financial performance data shows mixed results with reported revenues of $5.14 billion representing a +1.4% year-over-year increase, while consensus estimates for the current quarter suggest a -1.9% decline. The company beat revenue expectations by 0.68% but missed earnings expectations exactly, reporting EPS of $0.73 versus an estimate of $0.78. Valuation metrics place the stock at par with peers, receiving a Zacks Value Style Score of C.
π BSX shares rose +10.2% last month, outperforming the S&P 500.
π Quarterly revenue hit $5.14 billion, up +1.4% year-over-year.
π° EPS of $0.73 missed consensus estimates by 6.7%.
π Analysts lowered quarterly and fiscal year earnings estimates by ~2.5-2.6%.
π Zacks Rank #5 (Strong Sell) assigned due to negative estimate trends.
π Boston Scientific shares have returned +10.2% over the past month, outperforming the S&P 500 composite which fell -2%.
π The company reported quarterly revenues of $5.14 billion, a +1.4% increase year-over-year, beating consensus estimates by 0.68%.
π° Reported earnings per share were $0.73, missing the Zacks Consensus Estimate of $0.78 by approximately 6.7%.
π Analysts have revised the current quarter's earnings estimate down by -2.5% and the fiscal year estimate down by -2.6% over the last month.
π Boston Scientific received a Zacks Rank #5 (Strong Sell) due to negative trends in earnings estimate revisions.
π΅ The company holds a Zacks Value Style Score of C, indicating it is currently trading at par with its industry peers.
Bullish Signals
Quarterly revenue reached $5.14 billion, up 1.4%.
Beat consensus revenue estimate by 0.68%.
Risk Factors
Analysts cut quarterly earnings estimate by -2.5%.
Fiscal year consensus dropped -2.6% recently.
Missed EPS of $0.78 vs actual $0.73.
Assigned Zacks Rank #5 (Strong Sell).
Bullish Signals
Boston Scientific reported quarterly revenues of $5.14 billion, representing a +1.4% year-over-year increase.
The company beat the Zacks Consensus Revenue Estimate for the current quarter by +0.68%.
Risk Factors
Analysts have revised the consensus earnings estimate for the current quarter down by -2.5% from the year-ago period.
The Zacks Consensus Estimate for the current fiscal year has decreased by -2.6% over the last 30 days.
Boston Scientific missed the quarterly EPS consensus estimate of $0.78, reporting actual earnings of $0.73 per share.
The company has been assigned a Zacks Rank #5 (Strong Sell), suggesting it may underperform the broader market in the near term.
Boston Scientific (BSX) stock has underperformed its healthcare peer group, dropping 56.8% year-to-date as of November 3, 2026, and trading at the lowest price-to-earnings multiple among six major rivals. Despite this valuation discount, the company ranks third in revenue growth and operating margins over the last four quarters, reporting an 8.9% revenue increase compared to Stryker's 7.9% and Medtronic's 9.8%. However, the market appears to price in significant headwinds regarding specific product lines that are currently struggling with market share erosion.
Underlying the stock's weakness is a distinct slowdown in sales growth across all quarters of fiscal year 2026, which decelerated from 15.9% in Q4 2025 to just 1.4% in Q3 2026. Management attributes this sharp decline primarily to a cyber incident that halted production and shipping for eight days, as well as competitive pressures in its EP and WATCHMAN businesses. Consequently, the company has revised its full-year 2026 revenue growth guidance down to 4.3% from an earlier estimate of 6.0%, signaling that current performance is insufficient to offset losses in key segments.
Looking ahead, Boston Scientific expects fourth-quarter revenue to decline by 1% to 3% as customers work through inventory built up during the recent cyber incident. Management warns that 2027 will be a trough period where sales and adjusted earnings per share face challenges, with some major product platforms slipping by six months in development. The company anticipates a return to high performance only in 2028, contingent on the launch of new products in early 2028 and meaningful improvement in its EP segment, which is expected to lose market share until that time.
Investors are closely watching the February 2027 earnings report for signs of recovery in the EP and WATCHMAN segments, which currently account for significant pressure on overall sales. While the rest of the company, including interventional cardiology, continues to grow at a healthy 19% rate, management indicates that this growth will not be enough to offset the drag from these two specific businesses in 2027. The stock's low valuation reflects market skepticism about whether Boston Scientific can regain its competitive footing without a successful product launch or significant share recovery in its struggling divisions.
π BSX stock dropped 56.8% YTD, trading at lowest P/E among six peers.
π Revenue growth slowed to 1.4% in Q3 due to cyber incident and competition.
π» Cyber halt revised full-year guidance to 4.3% from previous 6.0% estimate.
π₯ WATCHMAN sales fell 7% in U.S., dragging down overall revenue performance.
π Management forecasts trough in 2027 with recovery expected only in 2028.
π BSX stock dropped 56.8% year-to-date as of November 3, 2026, trading at the lowest P/E multiple among six major healthcare peers despite ranking third in revenue growth and operating margins.
π Revenue growth slowed sequentially across all quarters in fiscal 2026, decelerating from 15.9% in Q4 to just 1.4% in Q3 due to a cyber incident and competitive pressures.
π» A cyber incident caused an eight-day production halt, contributing to a revised full-year 2026 revenue growth guidance of 4.3%, down from the previous 6.0% estimate.
π Sales in the EP business fell 5% in Q3 and are expected to continue losing market share until a new product launches in early 2028.
π₯ WATCHMAN sales declined 7% in the U.S., adding pressure to overall revenue as management expects these two segments to drag down performance in 2027.
π Management forecasts a trough in 2027 with declining fourth-quarter revenue of 1% to 3%, anticipating a return to high performance only in 2028.
π Investors are focused on the February 2027 earnings report for critical updates on EP and WATCHMAN segment recovery and new product launch timelines.
Bullish Signals
Ranks third among peers for revenue growth and margins.
Management expects high performance return by 2028.
Risk Factors
Revenue growth slowed to 1.4% in Q3 due to cyber incident.
Q4 revenue expected to fall 1-3% as customers work through inventory.
EP sales fell 5% with market share erosion until 2028 launch.
WATCHMAN sales declined 7% in U.S., lowering multiple relative to rivals.
2027 projected as trough delaying recovery until 2028.
Bullish Signals
Boston Scientific ranks third among six healthcare peers for both revenue growth and operating margin over the latest four quarters, demonstrating resilient core business performance.
The company's interventional cardiology business is growing consistently at 19%, offsetting some of the drag from its struggling EP and WATCHMAN segments.
Management expects to return to high performance in 2028 following a projected trough, suggesting potential for significant stock re-rating if product launches succeed.
Risk Factors
Revenue growth has slowed in every quarter of fiscal 2026, dropping from 15.9% in Q4 to just 1.4% in Q3 due to a cyber incident and competitive erosion.
Management expects fourth-quarter revenue to fall 1% to 3% as customers work through inventory built up after the recent cyber incident.
Sales in the EP business fell 5% in Q3, with management warning that market share will continue to erode until a new product launches in early 2028.
WATCHMAN sales declined 7% in the U.S., contributing to overall revenue pressure and lowering the company's multiple relative to rivals.
Management projects 2027 as a trough period where sales and adjusted earnings per share will be challenged, delaying recovery until 2028.
Guidance loweredNew AI featuresRegulatory approvalAI-generated analysis
Boston Scientific reported slower third-quarter growth with net sales rising just 1.5% to $5.138 billion, while adjusted earnings per share declined year over year. The company subsequently lowered its near-term outlook, projecting a fourth-quarter sales decline between 1% and 3% compared to the prior-year quarter.
Management forecasts full-year 2026 reported sales growth of approximately 4.25% and organic growth of roughly 3.75%, with adjusted EPS expected to range from $3.16 to $3.18. For the third quarter specifically, adjusted EPS is forecast at $0.77 to $0.79, following a drop to $0.73 in the previous quarter.
The company cited an August cybersecurity incident that disrupted operations as a factor influencing its revised near-term sales outlook. Despite this operational pressure, Boston Scientific highlighted progress in its longer-term pipeline, including new device clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter.
π Q3 net sales rose 1.5% to $5.138 billion despite slower growth.
π Adjusted EPS fell to $0.73, prompting a lowered full-year outlook.
π Cybersecurity incident in August disrupted operations and reduced near-term guidance.
π Cardiovascular and MedSurg sales increased 1.9% and 0.6% respectively.
π Received U.S. clearances for StoneSmart kidney-stone technologies and SEISMIQ catheter.
π Boston Scientific lowered its fourth-quarter sales outlook to a projected decline of 1% to 3% year over year following slower third-quarter growth.
π° Third-quarter net sales reached $5.138 billion, representing a modest 1.5% increase from the prior-year quarter.
π Adjusted earnings per share fell to $0.73 in Q3 from $0.75 a year earlier, with GAAP EPS dropping to $0.40.
π An August cybersecurity incident disrupted operations and contributed to the company's decision to reduce its near-term sales guidance.
π Cardiovascular sales rose 1.9% while MedSurg sales increased 0.6% during the third quarter.
π The company received U.S. clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter.
π¬ Enrollment began in the Elite AF trial for the next-generation WATCHMAN Elite device to support its longer-term portfolio.
π€ Boston Scientific entered a strategic collaboration with Heartflow on AI-assisted planning for coronary interventions.
π Full-year 2026 adjusted EPS is projected at $3.16 to $3.18 with reported sales growth of approximately 4.25%.
Bullish Signals
StoneSmart kidney-stone tech received U.S. clearances.
Elite AF trial enrollment begins for WATCHMAN Elite.
Heartflow AI collaboration enhances coronary intervention planning.
Cardiovascular sales rose 1.9% in Q3.
Risk Factors
Q4 sales expected to decline 1%-3% YoY due to slower growth.
Boston Scientific received U.S. clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter, expanding its product portfolio.
The company began enrolling patients in the Elite AF trial for the next-generation WATCHMAN Elite device, supporting its longer-term pipeline growth.
Boston Scientific entered a strategic collaboration with Heartflow on AI-assisted planning for coronary interventions to enhance procedural capabilities.
Cardiovascular sales rose 1.9% and MedSurg sales increased 0.6% in the third quarter, demonstrating resilience across key segments.
Risk Factors
Boston Scientific expects fourth-quarter sales to decline between 1% and 3% year over year due to slower growth momentum.
Adjusted earnings per share declined year over year in the third quarter, falling from $0.75 to $0.73.
An August cybersecurity incident disrupted operations, leading management to lower its near-term sales outlook.
Clinical trial resultsDevice clearanceNew AI featuresAI-generated analysis
Boston Scientific reported third-quarter net sales of USD 5.138 billion, representing a 1.5% increase on reported, operational, and organic bases compared to the prior year. The company delivered adjusted earnings per share of USD 0.73 and GAAP earnings per share of USD 0.40, contrasting with the previous year's figures of USD 0.51 for GAAP EPS.
The medical technology firm announced several significant pipeline milestones alongside its financial results. Key developments include the initiation of enrollment in the Elite AF clinical trial for its next-generation WATCHMAN Elite device and receiving FDA 510(k) clearances for the Navigator Flex Ureteral Access Sheath Set, the LithoVue Elite ureteroscope, and an expanded size range for its SEISMIQ intravascular lithotripsy peripheral catheter.
Looking ahead, management issued a weaker near-term sales outlook due to ongoing cybersecurity disruptions affecting operations. The company expects fourth-quarter reported and organic sales to decline between 1.0% and 3.0% year over year. Full-year 2026 guidance projects reported sales growth of 4.25% and organic growth of 3.75%, with adjusted earnings per share forecasted between USD 3.16 and USD 3.18.
π Q3 net sales rose 1.5% to USD 5.138 billion across all bases.
π Elite AF trial enrollment began for next-gen WATCHMAN Elite device.
β FDA cleared Navigator Flex sheath and LithoVue Elite ureteroscope sets.
π§ Expanded SEISMIQ catheter size range received additional FDA clearance.
β οΈ Q4 sales expected to drop 1-3% due to cybersecurity disruptions.
π Boston Scientific achieved third-quarter net sales of USD 5.138 billion, marking a 1.5% increase on reported, operational, and organic bases.
π The company initiated enrollment in the Elite AF trial for its next-generation WATCHMAN Elite left atrial appendage closure device.
β Boston Scientific received FDA 510(k) clearance for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite single-use digital flexible ureteroscope.
π§ The firm secured further FDA clearance for an expanded size range of its SEISMIQ intravascular lithotripsy peripheral catheter.
π€ Boston Scientific highlighted a collaboration with Heartflow to advance artificial-intelligence-supported computed tomography planning for percutaneous coronary intervention.
β οΈ Management expects fourth-quarter reported and organic sales to decline between 1.0% and 3.0% year over year due to cybersecurity disruptions.
π Full-year 2026 guidance forecasts reported sales growth of 4.25% and organic growth of 3.75%.
Bullish Signals
Q3 net sales rose 1.5% to USD 5.138 billion.
Risk Factors
Q4 sales expected to drop 1-3% due to cyber disruptions.
Revenue pressured by ongoing cybersecurity operational challenges.
Bullish Signals
Boston Scientific achieved third-quarter net sales of USD 5.138 billion, representing a 1.5% increase on reported, operational, and organic bases.
The company initiated enrollment in the Elite AF clinical trial for its next-generation WATCHMAN Elite device, advancing its pipeline in left atrial appendage closure.
Boston Scientific received FDA 510(k) clearance for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite single-use digital flexible ureteroscope with temperature sensing.
The firm secured further FDA clearance for an expanded size range of its SEISMIQ intravascular lithotripsy peripheral catheter, broadening its product portfolio.
Boston Scientific highlighted a strategic collaboration with Heartflow to advance artificial-intelligence-supported computed tomography planning for percutaneous coronary intervention.
Risk Factors
Management expects fourth-quarter reported and organic sales to decline between 1.0% and 3.0% year over year due to ongoing cybersecurity disruptions affecting operations.
The company faces near-term revenue pressure as it navigates operational challenges stemming from the cybersecurity incident.
Boston Scientific (BSX) shares fell approximately 6% to $42 following its Q3 2026 earnings report, which missed analyst expectations for adjusted EPS of $0.73 and organic revenue growth of 1.5%. While trailing twelve-month net profit margins improved to 16.6% from 14.4%, the specific quarter saw a significant decline in net income, dropping 22.9% year-over-year to $582 million compared to $755 million in the prior period.
The company's performance highlights a divergence between its growth ambitions and current execution across key segments. While Neuromodulation grew 13% and IO&E delivered 5% growth, core areas like Urology, Endoscopy, and CRM declined by 2-3%. Consequently, adjusted operating margins contracted by 150 basis points, signaling that the company has not yet successfully turned its broader segment and margin story into consistent execution despite new product introductions.
Specific headwinds in established product lines are expected to persist through 2027. WATCHMAN revenue fell 6% with standalone volumes down significantly, while Electrophysiology (EP) declined 5% overall with a sharper 8% drop in the U.S. Management explicitly flags continued weakness in these areas, suggesting that reimbursement constraints and hospital capacity issues may limit demand translation into higher net margins for the foreseeable future.
π Stock slid 6% after Q3 EPS missed guidance and organic revenue grew only 1.5%.
π° Net income dropped 22.9% YoY to $582M despite trailing twelve-month margin improvement to 16.6%.
β οΈ WATCHMAN revenue fell 6% with standalone volumes down in the high teens.
π₯ EP revenue declined 5% overall, including an 8% U.S. drop due to capacity constraints.
ποΈ Management warns WATCHMAN and EP weakness will extend into 2027.
π Boston Scientific stock slid nearly 6% to $42 after Q3 2026 adjusted EPS of $0.73 missed guidance and organic revenue growth of only 1.5%.
π° Net income for the quarter dropped sharply by 22.9% year-over-year to $582 million, contrasting with a trailing twelve-month margin improvement to 16.6%.
π Core segments faced headwinds as Urology revenue declined 3%, Endoscopy slipped 1%, and CRM fell 2% despite growth in Neuromodulation.
π Adjusted operating margins contracted by 150 basis points, indicating execution challenges in smoothing revenue from new products and tuck-in deals.
β οΈ WATCHMAN revenue fell 6% with standalone volumes down by the high teens, extending concerns about chronic drags on earnings.
π₯ Electrophysiology (EP) revenue declined 5% overall, with a significant 8% drop in the U.S. market due to capacity constraints.
ποΈ Management has flagged continued weakness in WATCHMAN and EP segments extending into 2027, confirming near-term headwinds.
π The company cites reimbursement limits and hospital capacity constraints as primary factors limiting demand translation for key procedures.
Bullish Signals
Net profit margins improved to 16.6% from 14.4%.
Neuromodulation segment grew 13% year-over-year.
IO&E delivered solid 5% growth.
Risk Factors
Operating margins contracted 150 bps in Q3 2026 due to revenue decline.
WATCHMAN revenue fell 6% with volumes down high teens.
Management warns of continued WATCHMAN and EP weakness into 2027.
Bullish Signals
Trailing twelve-month net profit margins improved significantly to 16.6% from 14.4%, demonstrating underlying profitability strength despite the quarterly miss.
Neuromodulation segment grew 13% year-over-year, driven by the Nalu acquisition and higher value procedures gaining traction.
IO&E (Interventional Oncology & Endoscopy) delivered solid 5% growth, aligning with the thesis of expanding footprint in high-growth procedure areas.
Risk Factors
Adjusted operating margins contracted by 150 basis points in Q3 2026, reflecting pressure from declining core segment revenues.
WATCHMAN revenue fell 6% with standalone volumes down by the high teens, indicating a potential chronic drag on earnings rather than a temporary soft spot.
Management explicitly warns of continued WATCHMAN and EP weakness extending into 2027, suggesting persistent headwinds in these established product lines.
Boston Scientific is preparing to release its third-quarter financial results before the market opens on October 28, 2026. The company's stock was trading at EUR 40.89 on October 26, 2026, reflecting a modest gain of 0.70% against the previous close. This pre-earnings activity sets the stage for investor anticipation regarding the upcoming quarterly performance report.
The company recently reported strong second-quarter results with revenue reaching USD 5.44 billion, representing a 7.50% year-over-year increase. Adjusted earnings per share hit USD 0.86, surpassing the consensus estimate of USD 0.83, while total revenue exceeded analyst expectations of USD 5.38 billion. These figures demonstrate solid operational growth ahead of the Q3 disclosure.
For the third quarter, Boston Scientific has provided adjusted earnings guidance ranging from USD 0.80 to USD 0.82 per share. This guidance range sits above the current analyst consensus estimate of approximately USD 0.746 per share and the projected revenue of USD 5.10 billion. The company also appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027.
π Boston Scientific releases Q3 results before market opens Oct 28, 2026.
π° Q2 revenue hit USD 5.44 billion, up 7.50% year-over-year.
π― Q3 adjusted earnings guidance set between USD 0.80 and USD 0.82.
π€ Joseph M. Fitzgerald appointed COO effective Jan 1, 2027.
π Boston Scientific is scheduled to release third-quarter results before the market opens on October 28, 2026.
π° The company reported second-quarter revenue of USD 5.44 billion, marking a 7.50% year-over-year increase.
π Adjusted earnings per share for the second quarter reached USD 0.86, beating the consensus estimate of USD 0.83.
π― Third-quarter adjusted earnings guidance is set between USD 0.80 and USD 0.82 per share.
π€ Joseph M. Fitzgerald was appointed as executive vice president and chief operating officer effective January 1, 2027.
π Analysts have a wide range of price targets, with recent reductions noted by brokerages like Leerink Partners.
π₯ The company operates in the Healthcare / Medical devices sector with a market capitalization of USD 66.2 billion.
Bullish Signals
Revenue rose 7.5% to $5.44B in Q2.
Risk Factors
Leerink cut target from $60 to $55.
Average target $68.23 below current price.
Bullish Signals
Boston Scientific reported second-quarter revenue of USD 5.44 billion, a significant 7.50% year-over-year increase.
The company beat analyst expectations for the second quarter with adjusted earnings per share of USD 0.86 versus a consensus of USD 0.83.
Second-quarter revenue of USD 5.44 billion exceeded the analyst estimate of USD 5.38 billion.
Risk Factors
Analyst price targets remain wide and volatile, with Leerink Partners recently cutting its target from USD 60.00 to USD 55.00.
The average 12-month analyst target of USD 68.23 is significantly lower than the current stock price, indicating mixed confidence in the full-year path.
Boston Scientific announced on October 7, 2026, that Joseph M. Fitzgerald will serve as its new Chief Operating Officer effective January 1, 2027. The company confirmed this leadership transition in a press release detailing the restructuring of its executive team.
Under the new organizational structure, Fitzgerald will oversee Boston Scientific's global operations, business units, and regions. Concurrently, the company plans to reorganize its reporting lines into three distinct segments: Interventional Therapies, Rhythm Solutions, and MedSurg, all effective on January 1, 2027.
Market data indicates Boston Scientific stock traded at EUR 40.77 during weekend sessions on October 25, 2026, according to Lang & Schwarz. The company's latest release focuses on the dated leadership change and the planned operating structure rather than immediate financial results.
π Joseph M. Fitzgerald appointed COO effective January 1, 2027.
ποΈ Three new reportable segments launching in Q1 2027.
π Stock traded at EUR 40.77 on October 25, 2026.
π Fitzgerald to oversee global operations under new structure.
π Boston Scientific named Joseph M. Fitzgerald as Chief Operating Officer effective January 1, 2027.
ποΈ The company will establish three new reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg starting in Q1 2027.
π Boston Scientific stock traded at EUR 40.77 during weekend sessions on October 25, 2026.
π The leadership announcement was made via a press release dated October 7, 2026.
π Fitzgerald will oversee the company's global operations and business units under the new structure.
Bullish Signals
Segments restructured into three units effective Jan 1, 2027.
Joseph M. Fitzgerald appointed COO for global ops.
Risk Factors
Weekend trading at EUR 40.77 differs from standard liquidity.
Bullish Signals
Boston Scientific is executing a strategic organizational restructuring by establishing three new reportable segments (Interventional Therapies, Rhythm Solutions, and MedSurg) effective January 1, 2027.
The appointment of Joseph M. Fitzgerald as COO signals confidence in leadership continuity as he takes over global operations oversight.
Risk Factors
Current stock price of EUR 40.77 reflects weekend trading conditions which may differ from standard market liquidity.
This article compares the financial outlook and operational metrics of Boston Scientific (BSX) and Becton Dickinson (BDX), focusing on recent guidance changes and market positioning. Boston Scientific has lowered its fiscal 2026 revenue growth forecast to a midpoint of 6.0% due to a sharp slowdown in its WATCHMAN device market and share losses in electrophysiology. Additionally, the company warned that a cyberattack disrupting manufacturing and shipments will materially impact its third-quarter and full-year 2026 results.
In contrast, Becton Dickinson raised its adjusted EPS forecast for fiscal 2026 but expects low single-digit revenue growth in 2027, citing headwinds from its Alaris business. While Boston Scientific currently boasts a higher operating margin of 21.0% compared to Becton Dickinson's 14.4%, management anticipates pressure on these margins in 2027 due to gross margin compression in key segments like WATCHMAN and the effects of its Penumbra deal.
The analysis highlights that Boston Scientific trades at a lower price-to-earnings multiple of 18.0 versus 55.7 for Becton Dickinson, though it pays no dividends compared to Becton Dickinson's 2.2% yield. Investors are advised to monitor Boston Scientific's Q3 2026 revenue report expected around October 28, 2026, as the company had previously guided for 3% to 5% growth before the cyberattack warning.
π Boston Scientific lowered fiscal 2026 revenue growth forecast to 6.0% midpoint.
β οΈ Cyberattack expected to materially impact Q3 and full-year 2026 results.
π° Operating margin reached 21.0% through June 30, 2026.
π Margins face pressure in 2027 from WATCHMAN and electrophysiology segments.
π¦ Boston Scientific trades at 18.0x earnings versus competitor's 55.7x multiple.
π Boston Scientific lowered its fiscal 2026 revenue growth forecast to a midpoint of 6.0%, down from 7.8% in April.
β οΈ A cyberattack disrupting manufacturing and shipments is expected to have a material impact on Boston Scientific's third-quarter and full-year 2026 results.
π Becton Dickinson raised its adjusted EPS forecast for fiscal 2026, projecting revenue growth toward the high end of its low single-digit range.
π° Boston Scientific recorded an operating margin of 21.0% over the four quarters to June 30, 2026, compared with 14.4% for Becton Dickinson.
π Boston Scientific management expects operating margins to come under pressure in 2027 due to gross margin pressure from WATCHMAN and electrophysiology.
π¦ Boston Scientific trades at 18.0 times earnings, significantly lower than Becton Dickinson's 55.7 times earnings multiple.
πΈ Becton Dickinson maintains a dividend yield of 2.2%, whereas Boston Scientific does not pay any dividends.
π Boston Scientific revenue grew 16.2% on average over the last three twelve-month periods compared to 7.1% for Becton Dickinson.
π Investors are advised to watch Boston Scientific's Q3 2026 revenue report expected around October 28, 2026.
Bullish Signals
Operating margin hit 21.0%, beating Becton Dickinson's 14.4%.
Revenue grew 16.2% vs competitor's 7.1% over three periods.
Risk Factors
2026 revenue growth forecast lowered to 6.0% midpoint.
Cyberattack impacts Q3 and full-year 2026 results.
Operating margins pressured in 2027 by product mix.
WATCHMAN market slowed; rivals gain electrophysiology share.
Bullish Signals
Boston Scientific recorded a strong operating margin of 21.0% over the four quarters to June 30, 2026, significantly outperforming Becton Dickinson's 14.4%.
The company demonstrated robust revenue growth averaging 16.2% over the last three twelve-month periods compared to 7.1% for its competitor.
Risk Factors
Boston Scientific lowered its fiscal 2026 revenue growth forecast to a midpoint of 6.0%, down from 7.8% in its April release.
A cyberattack that disrupted manufacturing and shipments is likely to have a material impact on the company's third-quarter and full-year 2026 results.
Management expects operating margins to come under pressure in 2027 due to gross margin pressure from WATCHMAN, electrophysiology, and the first effects of its Penumbra deal.
The U.S. market for the WATCHMAN device has slowed sharply, with rivals taking share from the company's electrophysiology business.
Boston Scientific Corporation announced on October 7, 2026, a significant organizational restructuring set to take effect on January 1, 2027. The company named Joseph M. Fitzgerald as its new Chief Operating Officer, effective the start of 2027, where he will oversee global operations, business units, and regions.
As part of this strategic shift, Boston Scientific will establish three distinct reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg. This new operating model is designed to facilitate faster decision-making processes and improve the allocation of investments across the company's diverse portfolio.
The leadership transition marks a key milestone in the company's strategic evolution, aiming to streamline operations under Fitzgerald's guidance. The restructuring aligns with the company's long-term goals of enhancing operational efficiency and focusing resources on its core therapeutic areas.
Joseph M. Fitzgerald assumes his role as Executive Vice President and COO, signaling a clear path forward for Boston Scientific's management team. The announcement underscores the company's commitment to adapting its structure to better serve its stakeholders and drive future growth.
π€ Joseph M. Fitzgerald named Chief Operating Officer effective Jan 1, 2027.
π’ Boston Scientific establishes three new reportable segments: Interventional Therapies, Rhythm Solutions, MedSurg.
β‘ Restructuring aims to streamline operations and optimize investment allocation for BSX.
π€ Joseph M. Fitzgerald has been named Chief Operating Officer of Boston Scientific Corporation.
π Fitzgerald will officially assume his new role effective January 1, 2027.
π’ The company is establishing three new reportable segments to streamline operations.
πΌ The new segments are Interventional Therapies, Rhythm Solutions, and MedSurg.
β‘ This restructuring aims to support faster decision-making within the organization.
π° The new structure will optimize investment allocation across the company's portfolio.
π Boston Scientific is listed on the New York Stock Exchange under ticker BSX.
ποΈ The organizational changes are scheduled to take effect at the start of 2027.
Bullish Signals
Strategic restructuring enhances operational efficiency and decision-making.
Joseph M. Fitzgerald appointed COO for global ops.
Three new segments enable targeted investment allocation.
Bullish Signals
Boston Scientific is implementing a strategic restructuring designed to enhance operational efficiency and accelerate decision-making capabilities.
The appointment of Joseph M. Fitzgerald as COO signals strong leadership continuity and focus on global operations management.
The creation of three distinct reportable segments allows for more targeted investment allocation across the company's portfolio.
Mizuho Securities has lowered its price target for Boston Scientific from USD 60.00 to USD 55.00 while maintaining an Outperform rating, citing concerns over near-term procedure volume pressure linked to Affordable Care Act and Medicaid changes ahead of the October 28 earnings report.
Despite the analyst downgrade, Boston Scientific reported robust second-quarter financial performance with net sales reaching USD 5.44 billion, representing a 7.5% year-over-year increase. Adjusted earnings per share rose 15% to USD 0.86, demonstrating strong operational execution despite macroeconomic headwinds in the medical device sector.
The company is also undergoing strategic restructuring with Joseph M. Fitzgerald set to become Chief Operating Officer on January 1, 2027. This leadership change will reorganize the business into three distinct reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg, aiming to streamline operations and clarify growth drivers.
Trading at approximately USD 43.31 as of mid-October 2026, Boston Scientific remains well below its 52-week high but maintains a significant market capitalization of USD 64.4 billion. Investors are closely watching the upcoming third-quarter results to determine if procedure volume pressures will impact the momentum established in the second quarter.
π Mizuho cuts price target to $55 while maintaining Outperform rating.
π° Q2 net sales rose 7.5% year-over-year to $5.44 billion.
π Adjusted EPS increased 15% to $0.86 in Q2 2026.
π Joseph Fitzgerald appointed new COO effective January 1, 2027.
π Mizuho cut its price target for Boston Scientific from USD 60.00 to USD 55.00 while keeping an Outperform rating.
π° Second-quarter net sales reached USD 5.44 billion, up 7.5% year over year on a reported basis.
π Adjusted earnings per share increased 15% to USD 0.86 in the second quarter of 2026.
π Joseph M. Fitzgerald is named new Chief Operating Officer starting January 1, 2027.
ποΈ The company will restructure into three segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
β οΈ Analysts cite potential procedure volume pressure from Affordable Care Act and Medicaid changes as a risk.
π Third-quarter earnings results are scheduled for release on October 28, 2026.
π΅ Market capitalization stands at USD 64.4 billion as of October 13, 2026.
π Stock traded at USD 43.31 with a 52-week range between USD 41.39 and USD 105.65.
Bullish Signals
Revenue grew 7.5% YoY to USD 5.44 billion.
Adjusted EPS surged 15% to USD 0.86.
Restructuring into three focused operational segments.
Appointed new COO Joseph M. Fitzgerald.
Risk Factors
Mizuho cut price target 8.33% to $55 due to volume pressure.
ACA/Medicaid changes may hurt H2 2026 procedure volumes.
Bullish Signals
Boston Scientific reported strong second-quarter revenue growth of 7.5% year over year, reaching USD 5.44 billion in net sales.
Adjusted earnings per share surged 15% to USD 0.86, indicating resilient profitability despite market headwinds.
The company is executing a strategic restructuring plan to organize operations into three focused segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
Joseph M. Fitzgerald is appointed as the new Chief Operating Officer, signaling continued investment in leadership and operational efficiency.
Risk Factors
Mizuho lowered its price target by 8.33% to USD 55.00 due to concerns over near-term procedure volume pressure.
Analysts warn that changes involving the Affordable Care Act and Medicaid could negatively impact future procedure volumes in the second half of 2026.
Data breachGuidance loweredOperational disruptionAI-generated analysis
Boston Scientific reported Q2 2026 revenue of USD 5.442 billion, representing a 7.5% increase from the prior year, with adjusted EPS reaching USD 0.86 against a consensus estimate of USD 0.83. Despite this financial beat, the company faces significant operational headwinds following a cybersecurity incident identified on August 25, 2026, which disrupted manufacturing and customer shipments.
Although distribution centers and most facilities resumed activity by early September, Reuters reported that Boston Scientific no longer expects to meet its earlier third-quarter and full-year 2026 forecasts. The company is scheduled to provide an updated outlook on October 28, 2026, which will serve as a critical checkpoint for investors to assess shipment recovery, revenue recapture, and the path toward its 2027 growth framework.
Market sentiment remains mixed as Citigroup lowered its price target from USD 50 to USD 48 on October 5, citing the operational disruption, while maintaining a neutral rating. However, broader analyst consensus remains Moderate Buy with an average price target of USD 67.88, suggesting that the market views the current stock price of approximately USD 42.55 as undervalued relative to long-term potential despite near-term execution risks.
π Q2 2026 revenue hit USD 5.442 billion, up 7.5% year-over-year.
Oppenheimer has downgraded its price target for Boston Scientific stock from USD 85.00 to USD 65.00 following a significant cybersecurity incident that disrupted the company's manufacturing, order processing, and shipment operations. This negative analyst action reflects concerns regarding the impact of the breach on near-term execution and the ability to meet previously issued financial forecasts for the third quarter and full year of 2026.
Despite the cyberattack, Boston Scientific reported strong second-quarter performance with revenue reaching USD 5.44 billion, a 7.50% increase year over year that exceeded analyst expectations of USD 5.38 billion. Adjusted earnings per share also beat consensus at USD 0.86 versus the expected USD 0.83, demonstrating underlying business resilience even as the company faces operational headwinds from the security breach.
The company plans to release an updated financial outlook alongside its third-quarter results on October 28, 2026, which will serve as a critical checkpoint for investors assessing the timeline of operational recovery and revised guidance. As of mid-October 2026, Boston Scientific maintains a market capitalization of USD 63.3 billion while trading around EUR 38.00, with the stock price reflecting mixed signals between recent earnings beats and the looming risks from the cyber incident.
π Oppenheimer cut BSX target to USD 65 due to cyber incident.
π Cyberattack caused BSX to miss Q3 and FY2026 forecasts.
π° BSX Q2 revenue hit USD 5.44B, beating analyst expectations.
ποΈ BSX will update outlook with Q3 results on October 28, 2026.
π Oppenheimer cut its target for Boston Scientific stock from USD 85.00 to USD 65.00 due to a cybersecurity incident disrupting operations.
π A recent cyberattack prevented Boston Scientific from meeting its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts.
π° Q2 2026 revenue reached USD 5.44 billion, up 7.50% year over year, exceeding the USD 5.38 billion analyst expectation.
π Adjusted earnings per share hit USD 0.86, beating the USD 0.83 consensus despite operational disruptions.
ποΈ The company will provide an updated outlook with third-quarter results on October 28, 2026.
π’ Boston Scientific has a market capitalization of USD 63.3 billion as of October 5, 2026.
π Stock traded at EUR 38.00 on October 5, 2026, up 0.34% versus the prior close.
π‘οΈ The cybersecurity incident disrupted manufacturing, order processing, and shipments for Boston Scientific.
Bullish Signals
Q2 2026 revenue hit $5.44B, up 7.50% YoY.
Risk Factors
Oppenheimer downgraded price target from USD 85.00 to USD 65.00 due to cyber incident.
Bullish Signals
Boston Scientific reported Q2 2026 revenue of USD 5.44 billion, representing a 7.50% year-over-year increase that exceeded analyst expectations.
The company achieved adjusted earnings per share of USD 0.86 in the second quarter, surpassing the USD 0.83 consensus estimate.
Despite operational disruptions from a cyberattack, Boston Scientific demonstrated underlying business strength with revenue and earnings beats.
Risk Factors
Oppenheimer downgraded its price target for Boston Scientific stock from USD 85.00 to USD 65.00 following a cybersecurity incident.
A recent cyberattack disrupted Boston Scientific's manufacturing, order processing, and shipments, impacting operational efficiency.
The security breach is likely to prevent Boston Scientific from meeting its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts.
Boston Scientific stock fell 1.46% to $42.60 on October 2, 2026, following a cybersecurity incident that raised concerns about the company's ability to meet its previously issued guidance for the third quarter and full year. The company disclosed unauthorized activity starting August 25, 2026, which disrupted manufacturing, order processing, and customer shipments, though distribution was substantially restored by the time of the report.
Despite the cyber risk, Boston Scientific reported strong second-quarter 2026 financial results with revenue rising 7.5% to $5.442 billion and GAAP net income increasing to $907 million. However, the incident led to a significant downgrade from analyst Oppenheimer, which cut its price target from $85 to $65, while other analysts maintain a moderate buy consensus with an average target of $70.19.
The company faces ongoing operational challenges including weaker momentum in its WATCHMAN product line and competitive pressure in the electrophysiology sector. Investors are now focused on the upcoming earnings call scheduled for October 28, 2026, where Boston Scientific plans to provide an updated operational and financial outlook regarding the impact of the cyber incident.
π Stock dropped 1.46% after cyber incident threatened Q3 guidance.
π» Unauthorized activity disrupted manufacturing starting August 25, 2026.
π Q2 revenue grew 7.5% YoY to $5.442 billion.
π» Oppenheimer lowered price target from $85 to $65.
β οΈ WATCHMAN line faces weaker momentum and EP competition.
π Boston Scientific stock dropped 1.46% to $42.60 after a cybersecurity incident threatened its Q3 and full-year guidance.
π» Unauthorized activity began on August 25, 2026, disrupting manufacturing and shipments before distribution was substantially restored.
π Q2 2026 revenue grew 7.5% year-over-year to $5.442 billion with GAAP net income rising to $907 million.
π» Analyst Oppenheimer lowered its price target from $85 to $65 due to concerns over the cyber incident's impact on guidance.
β οΈ The company faces weaker momentum in its WATCHMAN product line and competitive pressure in electrophysiology.
π Boston Scientific is scheduled to discuss third-quarter results and an updated outlook on October 28, 2026.
Oppenheimer cut target to $65 citing missed guidance risk.
Bullish Signals
Q2 2026 revenue increased 7.5% year-over-year to $5.442 billion, demonstrating underlying business strength despite the cyber incident.
GAAP net income attributable to common shareholders rose to $907 million from $797 million in the prior year period.
Risk Factors
A cybersecurity incident beginning August 25, 2026, disrupted manufacturing and order processing, raising risks to Q3 and full-year guidance.
Analyst Oppenheimer cut its price target from $85 to $65 due to concerns that the company may not meet previous net sales growth and adjusted EPS guidance.
Boston Scientific Corp. faces significant pressure to meet its fiscal 2026 guidance following a major cybersecurity incident that disrupted manufacturing, order processing, and shipments in late September 2026. The company had previously projected adjusted earnings between USD 3.28 and 3.32 per share for the full year, with third-quarter expectations of USD 0.80 to 0.82 per share. Reuters reported on September 8 that these targets were no longer expected to be met as the firm works through operational recovery.
Despite the cyber disruption, Boston Scientific reported robust second-quarter financial performance in Q2 2026, posting net sales of USD 5.44 billion, representing a 7.5% year-over-year increase. Diluted earnings per share reached USD 0.61 with an operating margin of 22.0%, establishing a strong operational base that the company must defend in its upcoming October 28 results. Major distribution centers and sterilization facilities remained largely functional, though supply execution timing was affected.
Analyst sentiment has turned cautious as Oppenheimer lowered its price target from USD 85 to USD 65 while maintaining an Outperform rating, citing the eight-day disruption and competitive pressures in left atrial appendage closure and electrophysiology. However, specific product lines showed resilience with WATCHMAN global sales growing 4.2% organically and electrophysiology revenue up 9.1%. The stock traded at USD 43.65 on September 30, reflecting a market reset as investors assess the long-term impact of the security breach on growth profiles.
Management plans to provide an updated operational and financial outlook with third-quarter results scheduled for release on October 28, 2026. The event serves as a critical inflection point where Boston Scientific must demonstrate that its underlying growth trajectory can withstand such disruptions. With a market capitalization of USD 64.9 billion, the company's ability to normalize operations quickly will be closely watched by investors evaluating its resilience against cyber threats and competitive headwinds.
π Q2 2026 sales hit $5.44B, up 7.5% YoY with $0.61 diluted EPS.
π Sept 8 cyberattack halted operations for eight days globally.
π Oppenheimer cut price target to $65 citing disruption and competition.
β‘ Electrophysiology revenue grew 9.1% organically in Q2 2026.
π Updated outlook released with Q3 results on Oct 28, 2026.
π Boston Scientific missed its third-quarter and full-year 2026 sales and adjusted earnings guidance due to a cybersecurity incident disrupting manufacturing and shipments.
π° Second-quarter 2026 net sales reached USD 5.44 billion, up 7.5% year over year, with diluted EPS of USD 0.61 and an operating margin of 22.0%.
π A major cyberattack on September 8 disrupted operations for eight days, affecting order processing and supply execution timing across global facilities.
π Oppenheimer analyst Suraj Kalia cut the price target from USD 85 to USD 65 while maintaining an Outperform rating due to the disruption and competition.
π₯ WATCHMAN global sales grew 4.2% organically in Q2 2026, demonstrating resilience in the left atrial appendage closure segment despite broader challenges.
β‘ Electrophysiology revenue grew 9.1% organically in Q2 2026, showing strong performance in a key growth area for the medical device company.
π The company plans to release an updated operational and financial outlook with third-quarter results on October 28, 2026.
π Major distribution centers processed orders at normal levels while sterilization facilities remained operational during the recovery phase.
π Stock price stood at USD 43.65 on September 30, 2026, trading USD 1.45 above the 52-week low of USD 42.20.
πΌ Boston Scientific maintains a market capitalization of USD 64.9 billion as it navigates the operational reset following the security breach.
Bullish Signals
Q2 2026 net sales hit USD 5.44B, up 7.5% YoY.
EPS reached USD 0.61 with a 22.0% operating margin.
WATCHMAN global sales grew 4.2% organically in Q2.
Electrophysiology revenue rose 9.1% organically in Q2 2026.
Risk Factors
Missed Q3/2026 guidance after major cyber incident.
Bullish Signals
Second-quarter 2026 net sales reached USD 5.44 billion, representing a 7.5% year-over-year increase that establishes a strong operational base.
Diluted earnings per share of USD 0.61 and an operating margin of 22.0% in Q2 2026 demonstrate robust underlying profitability.
WATCHMAN global sales grew 4.2% organically in fiscal second-quarter 2026, indicating resilience in a key product line.
Electrophysiology revenue achieved 9.1% organic growth in Q2 2026, highlighting strength in a strategic high-growth segment.
Major distribution centers and sterilization facilities remained operational at or above normal levels during the recovery period.
Risk Factors
The company missed its third-quarter and full-year 2026 sales and adjusted earnings guidance following a significant cybersecurity incident.
An eight-day disruption to manufacturing, order processing, and shipments forced a reset of operational expectations for fiscal 2026.
Oppenheimer analyst Suraj Kalia cut the price target from USD 85 to USD 65 citing the cyber disruption and competitive pressures.
The cybersecurity incident disrupted supply execution and the timing of customer orders, potentially affecting earnings leverage.
Boston Scientific must now prove that operational recovery can protect its underlying growth profile after the security breach.
Boston Scientific Corp. (BSX) faces a significant analyst price-target reduction from Oppenheimer, which lowered its target to USD 65.00 from USD 85.00 on September 21, 2026. This downgrade follows an August cybersecurity incident that disrupted manufacturing and shipments, with the company stating in a September 8 filing that the event is likely to materially impact third-quarter and full-year 2026 results.
Despite the operational setbacks, Boston Scientific reported strong second-quarter financial performance with net sales rising 7.5% to USD 5.442 billion. Adjusted earnings per share reached USD 0.86, surpassing the company's guidance range of USD 0.82 to USD 0.84. The Cardiovascular business drove growth with USD 3.624 billion in sales, while MedSurg sales increased by 5.9% to USD 1.818 billion.
Analyst sentiment remains mixed but generally positive regarding the long-term outlook, with an average 12-month price objective of USD 70.19 across thirty-one research firms. While Wells Fargo also cut its target slightly, the majority of analysts maintain buy ratings. The company expects to provide updated operational and financial guidance on October 28, 2026, following discussions of third-quarter results.
Manufacturing has resumed across most global facilities, though major distribution centers are processing orders at normal or above-normal levels. The incident identified unauthorized activity on August 25, 2026, affecting order processing and customer shipments. With a market capitalization of USD 65.2 billion, the stock continues to trade within its 52-week range as investors weigh the cybersecurity fallout against robust quarterly revenue growth.
π Oppenheimer cut price target to USD 65 citing August cyber outage.
π» Cyber incident disrupted manufacturing and shipments in late August 2026.
π Q2 net sales rose 7.5% to USD 5.442 billion with EPS beat.
π Manufacturing resumed globally while distribution centers operate at normal levels.
π Incident expected to materially impact Q3 and full-year 2026 financial results.
π Oppenheimer cut Boston Scientific's price target from USD 85.00 to USD 65.00 on September 21, 2026, citing an August cybersecurity incident.
π» The company identified unauthorized activity on August 25, 2026, causing a network outage that disrupted manufacturing and shipments.
π Q2 net sales rose 7.5% to USD 5.442 billion, with adjusted EPS of USD 0.86 beating the USD 0.82-0.84 guidance range.
β€οΈ Cardiovascular business generated USD 3.624 billion in sales, up 8.3%, while MedSurg sales reached USD 1.818 billion, up 5.9%.
π Boston Scientific expects to update its operational and financial outlook on October 28, 2026, when discussing Q3 results.
π Manufacturing has resumed across most global facilities, though distribution centers are processing orders at normal or above-normal levels.
π The average 12-month price objective among thirty-one research firms is USD 70.19, with twenty-three buy ratings and six holds.
π Wells Fargo also lowered its target from USD 50.00 to USD 48.00 on September 23, 2026, despite retaining an Outperform rating.
π° Boston Scientific has a market capitalization of USD 65.2 billion and trades under the ticker BSX on the New York Stock Exchange.
π The cybersecurity incident is expected to have a material impact on third-quarter and full-year 2026 financial results.
Bullish Signals
Q2 net sales rose 7.5% to USD 5.442 billion.
Risk Factors
Oppenheimer cut target from $85 to $65 due to cyber incident.
Bullish Signals
Boston Scientific reported Q2 net sales of USD 5.442 billion, representing a 7.5% increase from the prior year period.
Adjusted earnings per share reached USD 0.86 in the second quarter, exceeding the company's guidance range of USD 0.82 to USD 0.84.
The Cardiovascular business delivered strong growth with USD 3.624 billion in sales, up 8.3% year-over-year.
MedSurg sales increased by 5.9% to reach USD 1.818 billion during the second quarter.
Manufacturing operations have resumed across most global facilities following the recent cybersecurity incident.
Major distribution centers are currently processing orders at or above normal operating levels.
Risk Factors
Oppenheimer cut its price target from USD 85.00 to USD 65.00 due to an August cybersecurity incident disrupting operations.
The company identified unauthorized activity on August 25, 2026, which caused a network outage affecting manufacturing and shipments.
Boston Scientific stated the cybersecurity incident is likely to have a material impact on third-quarter and full-year 2026 results.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)